Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET
Neuro-Oncology · 04.05.2023 · 25 (5) · 984-994
DOI: 10.1093/neuonc/noac229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 10.10.2022. Verfasst von Michael M Wollring und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy.
Methods
Thirty-six adult patients with WHO CNS grade 3 or 4 gliomas (glioblastoma, 69%) at recurrence (median number of recurrences, 1; range, 1–3) were retrospectively identified. Besides MRI, serial FET PET scans were performed at baseline and early after chemotherapy initiation (not later than two cycles). Tumor-to-brain ratios (TBR), metabolic tumor volumes (MTV), the occurrence of new distant hotspots with a mean TBR >1.6 at follow-up, and the dynamic parameter time-to-peak were derived from all FET PET scans. PET parameter thresholds were defined using ROC analyses to predict PFS of ≥6 months and OS of ≥12 months. MRI response assessment was based on RANO criteria. The predictive values of FET PET parameters and RANO criteria were subsequently evaluated using univariate and multivariate survival estimates.
Results
After treatment initiation, the median follow-up time was 11 months (range, 3–71 months). Relative changes of TBR, MTV, and RANO criteria predicted a significantly longer PFS (all P ≤ .002) and OS (all P ≤ .045). At follow-up, the occurrence of new distant hotspots (n ≥ 1) predicted a worse outcome, with significantly shorter PFS (P = .005) and OS (P < .001). Time-to-peak changes did not predict a significantly longer survival. Multivariate survival analyses revealed that new distant hotspots at follow-up FET PET were most potent in predicting non-response (P < .001; HR, 8.578).
Conclusions
Data suggest that FET PET provides complementary information to RANO criteria for response evaluation of lomustine-based chemotherapy early after treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
- Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Radiology, Division of Neuroradiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of General Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
ORCID-Profile: Philipp Lohmann, Gabriele Stoffels, Norbert Galldiks
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Wollring, M. M., Werner, J. M., Bauer, E. K., Tscherpel, C., Ceccon, G. S., Lohmann, P., Stoffels, G., Kabbasch, C., Goldbrunner, R., Fink, G. R., Langen, K. J., & Galldiks, N. (2023). Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. Neuro-Oncology, 25(5), 984-994. https://doi.org/10.1093/neuonc/noac229
Vancouver
Wollring MM, Werner JM, Bauer EK, Tscherpel C, Ceccon GS, Lohmann P, et al. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. Neuro-Oncology. 2023;25(5):984-994. doi:10.1093/neuonc/noac229
BibTeX
@article{Wollring2023,
author = {Wollring, Michael M and Werner, Jan-Michael and Bauer, Elena K and Tscherpel, Caroline and Ceccon, Garry S and Lohmann, Philipp and Stoffels, Gabriele and Kabbasch, Christoph and Goldbrunner, Roland and Fink, Gereon R and Langen, Karl-Josef and Galldiks, Norbert},
title = {Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {5},
pages = {984--994},
doi = {10.1093/neuonc/noac229}
}
EUVIMED